Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

The race for a COVID-19 vaccine is wildly unpredictable and full of variables.

Can Novavax's Coronavirus Vaccine Be Valued?

With NVAX stock, it's debatable whether vaccine quality will be its advantage. At today's prices, take a wait-and-see approach.

All Bets Are Off With Novavax, So Tread Carefully

Despite Moderna's head start in the COVID-19 vaccine race, Novavax has been -- and could continue to be -- the bigger winner.

Forget Moderna: Novavax Is the Coronavirus Vaccine Stock You'll Really Want to Watch

Novavax, Inc. (NASDAQ: NVAX) reported results from animal challenge studies of its coronavirus vaccine candidate Tuesday that reinforce the positive interim Phase 1 data the company released in early August.

Novavax's Coronavirus Vaccine Candidate Protects Against Viral Replication In Animal Studies

AstraZeneca

BioNTech SE

CureVac B.V

Inovio Pharmaceuticals

Moderna

Pfizer

Hope for a successful vaccine by the winter is fueling trials at a record pace.

COVID-19: The Real Results Are A Long Way Away

Novavax has failed at late-stage clinical trials before, but if its COVID-19 vaccine even has 50% efficacy it could open up a huge global opportunity.
The post Novavax Is the Ultimate Coronavirus Stock appeared first on InvestorPlace.

Novavax Is the Ultimate Coronavirus Stock

Here's why this popular coronavirus stock will further enrich investors.

3 Reasons to Buy Novavax Now

Novavax (NVAX) starts a phase IIb study in South Africa to evaluate the efficacy of its COVID-19 vaccine candidate NVX-CoV2373. Shares rise following this development.

Novavax Begins Phase IIb Coronavirus Vaccine Study in South Africa

In the race to bring a Covid-19 vaccine to market, Novavax just scored a major coup and that's super-bullish for NVAX stock.
The post This Mega-Scale Deal Just Gave You a Reason to Buy Novavax appeared first on InvestorPlace.

This Mega-Scale Deal Just Gave You a Reason to Buy Novavax

The trial will be conducted in South Africa, which is experiencing a winter surge of COVID-19.

Novavax Launches Midstage Coronavirus Vaccine Trial

Novavax, Inc. (NASDAQ: NVAX), which has been assiduously stitching up production and supply partnerships, announced Monday another milestone event in the clinical development of its coronavirus vaccine, codenamed NVX-CoV2373.

Novavax Kickstarts Phase 2b Efficacy Study Of Coronavirus Vaccine In South Africa With $15M Gates Funding

Novavax NVAX, +9.92% said it's beginning a Phase 2b clinical trial in South Africa to evaluate the efficacy of NVX-CoV2373, its COVID-19 vaccine candidate.

Novavax starting trial of COVID-19 vaccine in South Africa

GAITHERSBURG, Md., Aug.  17, 2020  (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the beginning of a Phase 2b clinical trial in South Africa to evaluate the efficacy of NVX-CoV2373, Novavax’ COVID-19 vaccine candidate. Dr. Shabir Madhi, Professor of Vaccinology at Wits University, will lead the clinical trial, which is supported in part by a $15 million grant from the Bill & Melinda Gates Foundation. NVX‑CoV2373 is a stable, prefusion protein made using Novavax’ proprietary nanoparticle technology and includes Novavax’ proprietary Matrix‑M™ adjuvant.

Novavax Initiates Efficacy Trial of COVID-19 Vaccine in South Africa

Altimmune

Vaxart

It’s tough to top quadruple-digit growth.

These 3 Surprising Stocks Have Beaten the Market in 2020 -- by a Lot

The deal also includes support for a phase 3 clinical trial in the country.

U.K. Government to Buy 60 Million Doses of Novavax COVID-19 Vaccine

Johnson & Johnson

The federal government will foot the bill for vaccines, while insurers and the CARES Act will cover the cost of administering them.

Coronavirus Vaccine Will Be Free for Americans, Says HHS Official

Novavax (NVAX) enters an agreement to provide the UK government with 60 million doses of its COVID-19 vaccine, NVX-CoV2373, if approved.

Novavax (NVAX) to Supply Coronavirus Vaccine to UK Government

Novavax shares rose after the company said it reached a deal with the U.K. to supply 60 million doses of its potential coronavirus vaccine.

Novavax shares rise after deal to provide 60 million doses of coronavirus vaccine to U.K.

GlaxoSmithKline

Sanofi

The U.S. has doled out billions to develop a vaccine against the coronavirus, locking in a minimum of 800 million doses so far.

The U.S. has already invested billions on potential coronavirus vaccines. Here's where the deals stand

Novavax, Inc (NASDAQ: NVAX) announced Friday it has reached terms with the government of the United Kingdom to supply 60 million doses of its COVID-19 vaccine, when, and if, it receives regulatory approval.

Novavax To Supply 60M Coronavirus Vaccine Doses To UK Under New Deal

GAITHERSBURG, Md., Aug.  14, 2020  (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced it has signed a Heads of Terms (Term Sheet) with the Government of the United Kingdom (UK) for the purchase of 60 million doses of NVX-CoV2373, Novavax’ COVID-19 vaccine, and a Phase 3 clinical trial to assess the efficacy of the vaccine in the UK population. Novavax will also expand its collaboration with FUJIFILM Diosynth Biotechnologies, which will manufacture the antigen component of NVX-CoV2373 from its Billingham, Stockton-on-Tees site in the UK, in addition to its sites in North Carolina and Texas in the United States. The FUJIFILM Diosynth Biotechnologies site in the UK is expected to produce up to 180 million doses annually, which further boosts the global supply of NVX-CoV2373 for additional markets.

Novavax and UK Government Announce Collaboration and Purchase Agreement for Novavax’ COVID-19 Vaccine Candidate

The company is adding to the already-massive production capacity it has lined up for its COVID-19 vaccine candidate.

Novavax Stock Is Up on Deal With SK Bioscience

Novavax stock rebounded Thursday, after a 30% downturn the two previous days, buoyed by a supply deal with South Korea and with a South Korean company, for its coronavirus vaccine candidate.

This Vaccine Maker Rebounds On Supply Deal After A Rough Spell

Close on the heels of reporting its quarterly results, Novavax, Inc. (NASDAQ: NVAX) announced a manufacturing and supply deal with a South Korean company on Thursday.

Novavax Rallies As It Strikes New COVID-19 Vaccine Manufacturing, Supply Partnership

Shares of Novavax Inc. NVAX, -16.76% rallied 2.8% in premarket trading Thursday, after the biotechnology company said it has entered into a development and supply agreement with South Korea-based SK Group subsidiary SK Bioscience for the antigen component of Novavax's COVID-19 vaccine candidate, NVX-CoV2373.

News for Novavax Stock (NVAX)